澳门太阳集团www7722138-首页|welcome

Research and Development
Strong, Innovation-driven R&D Capabilities
9 Compounds
in core pipeline
7 Compounds
in clinical studies
62 China & PTC
Patent Authorizations

from China and the Patent
Cooperation Treaty
6 Major New Drug Invention Projects;
7 Projects in Shanghai's Science & Technology Innovation Action Plan;
3 Personalized Pilot Science Technology and Projects of CAS
R&D Field
Cancer Types Covered by the R&D Pipeline
 
  • Lung
    Cancer
  • Breast
    Cancer
  • Gastric
    Cancer
  • Nasopharyngeal
    Cancer
Rich and Balanced Pipeline
Updated in October 2020
 
  • 9 compounds in core pipeline, including those in late clinical stage and pre-clinical stage
  • The compound targets in the late stage of development have been well-validated
  • Multiple potential best-in-class compounds are expected to be used in combination to treat major indications
Outstanding Talent
  • Leading scientists with outstanding achievements
  • Rich experience in successful drug approval & launch
  • Covering the entire span of oncology research and development
R&D Pipeline
Clinical Stage
 
Pipeline Profile Target Indication/
Potential indication
Rights Stage

Pre-clinical

 

Phase 1

 

Phase 2

 

Phase 3

 

NDA

Country/region
where the
product is launched
RMX3001
(Liporaxel)

Microtubule Stabilizer

It is the 1st oral paclitaxel developed globally. Its safety and ease of administration are expected to bring significant improvements to cancer patients. Based on the unique innovative process technology, it is absorbed through the gastrointestinal tract, thus avoiding premedication, and reducing side effects such as peripheral neuropathy.

NA Gastric Cancer China           Approved in Korea 
Breast Cancer China            
ON101

TCM

Reduce wound inflammation Increase epithelialization of epidermal tissues Promote collagen production Reduce formation of wound granulation tissues

NA Diabetic Foot Ulcer Mainland, China         Taiwan, China  
Lucitanib

Oral small molecule TKI targeting FGFR1-3, VEGFR1-3, PDGFR α/β, with significant efficacy and high safety Rapid oral absorption, with little food effects on PK Pivotal Phase II study ongoing in multiple sites nationwide for the treatment of various types of tumors Explore combinations with PD-1/PD-L1 antibody

FGFR1-3 Thymic Cancer Mainland, China      Pivotal Phase 2       
VEGFR1-3 Nasopharyngeal Carcinoma Mainland, China      Pivotal Phase 2, in combination with PD-1 antibody      
PDGFR α/β Small Cell Lung Cancer Mainland, China      in combination with chemotherapy    
Glumetinib

Clinical development strategy guided by unique biomarkers High selectivity to c-Met and long half-life Multiple studies ongoing in China/Japan/US; preliminary clinical efficacy hasbeen observed, with good safety

c-Met Exon-14 Skipping in Non-small Cell Lung Cancer Global      Pivotal Phase 2(China / Japan / US)      
c-Met Mutation in Non-small Cell Lung Cancer Global    

 in combination with PD-1 antibody

     
c-Met Mutation in Non-small Cell Lung Cancer Global  

 in combination with EGFR inhibitor (Asia)

     
CYH33

Highly active PI3Kα inhibitor Clinical development strategy guided by unique biomarkers Significant in vivo/vitro anti-tumor effects Preferable safety profile with little and reversible glycemia effects

PI3Kα Solid tumor Global            
Solid tumor Global  

 in combination with Olaparib (China / US / Australia)

     
Breast Cancer Breast cancer  

 in combination with ET +/- Palbociclib (China / Australia)

     
Pipeline
Profile

Microtubule Stabilizer

It is the 1st oral paclitaxel developed globally. Its safety and ease of administration are expected to bring significant improvements to cancer patients. Based on the unique innovative process technology, it is absorbed through the gastrointestinal tract, thus avoiding premedication, and reducing side effects such as peripheral neuropathy.

Target

N/A

Indication/ Potential indication 

Gastric Cancer

  • Stage

    Pre-clinical 

     
  •  

    Phase 1

     
  •  

    Phase 2

     
  •  

    Phase 3

     
  •  

    NDA

Breast Cancer

  • Stage

    Pre-clinical 

     
  •  

    Phase 1

     
  •  

    Phase 2

     
  •  

    Phase 3

     
  •  

    NDA

Country / region where the product is launched 

Approved in Korea 

Profile

TCM

Reduce wound inflammation Increase epithelialization of epidermal tissues Promote collagen production Reduce formation of wound granulation tissues

Target

N/A

Indication/
Potential
indication

Diabetic Foot Ulcer

  • Stage

    Pre-clinical

  •  

    Phase 1

     
  •  

    Phase 2

     
  •  

    Phase 3

     
  •  

    NDA

Profile

Oral small molecule TKI targeting FGFR1-3, VEGFR1-3, PDGFR α/β, with significant efficacy and high safety Rapid oral absorption, with little food effects on PK Pivotal Phase II study ongoing in multiple sites nationwide for the treatment of various types of tumors Explore combinations with PD-1/PD-L1 antibody

Target

FGFR1-3

Indication/
Potential
indication

Thymic Cancer

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

     
  •  

    Phase 3

  •  

    NDA

Target

VEGFR1-3

Indication/ Potential indication

Nasopharyngeal Carcinoma

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

     
  •  

    Phase 3

  •  

    NDA

Target

PDGFR α/β

Indication/ Potential indication

Small Cell Lung Cancer

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

     
  •  

    Phase 3

  •  

    NDA

Profile

Clinical development strategy guided by unique biomarkers High selectivity to c-Met and long half-life Multiple studies ongoing in China/Japan/US; preliminary clinical efficacy hasbeen observed, with good safety

Target

c-Met

Indication/ Potential indication

Exon-14 Skipping in Non-small Cell Lung Cancer

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

     
  •  

    Phase 3

  •  

    NDA

c-Met Mutation in Non-small Cell Lung Cancer

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

     
  •  

    Phase 3

  •  

    NDA

c-Met Mutation in Non-small Cell Lung Cancer

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

  •  

    Phase 3

  •  

    NDA

Profile

Highly active PI3Kα inhibitor Clinical development strategy guided by unique biomarkers Significant in vivo/vitro anti-tumor effects Preferable safety profile with little and reversible glycemia effects

Target

c-Met

Indication/
Potential indication

Solid tumor

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

  •  

    Phase 3

  •  

    NDA

Solid tumor

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

  •  

    Phase 3

  •  

    NDA

Breast Cancer

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

  •  

    Phase 3

  •  

    NDA

Follow Us
©2020 Haihe Biopharma Co., Ltd.
All Rights Reserved 沪ICP备12016151号-1